These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 18024399)
1. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Bamia C; Pouli A; Baltadakis I; Terpos E; Kyrtopoulos SA; Sfikakis PP Haematologica; 2007 Nov; 92(11):1505-12. PubMed ID: 18024399 [TBL] [Abstract][Full Text] [Related]
2. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412 [TBL] [Abstract][Full Text] [Related]
3. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Souliotis VL; Dimopoulos MA; Sfikakis PP Clin Cancer Res; 2003 Oct; 9(12):4465-74. PubMed ID: 14555520 [TBL] [Abstract][Full Text] [Related]
4. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199 [TBL] [Abstract][Full Text] [Related]
5. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998 [TBL] [Abstract][Full Text] [Related]
6. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
7. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045 [TBL] [Abstract][Full Text] [Related]
8. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
14. Stem-cell transplantation in multiple myeloma. Harousseau JL; Moreau P; Attal M; Facon T; Avet-Loiseau H Best Pract Res Clin Haematol; 2005; 18(4):603-18. PubMed ID: 16026740 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Efferth T; Fabry U; Osieka R Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294 [TBL] [Abstract][Full Text] [Related]
16. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705 [TBL] [Abstract][Full Text] [Related]
17. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Olivieri A; Corvatta L; Montanari M; Brunori M; Offidani M; Ferretti GF; Centanni M; Leoni P Bone Marrow Transplant; 1998 May; 21(10):1049-53. PubMed ID: 9632280 [TBL] [Abstract][Full Text] [Related]
18. Melphalan-induced DNA damage in p53(+/-) and wild type mice analysed by the comet assay. Cordelli E; Cinelli S; Lascialfari A; Ranaldi R; Pacchierotti F Mutat Res; 2004 Jun; 550(1-2):133-43. PubMed ID: 15135647 [TBL] [Abstract][Full Text] [Related]
19. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534 [TBL] [Abstract][Full Text] [Related]
20. Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. Stefanou DT; Episkopou H; Kyrtopoulos SA; Bamias A; Gkotzamanidou M; Bamia C; Liakou C; Bekyrou M; Sfikakis PP; Dimopoulos MA; Souliotis VL Br J Clin Pharmacol; 2012 Nov; 74(5):842-53. PubMed ID: 22432918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]